MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease.


Journal

Amyotrophic lateral sclerosis & frontotemporal degeneration
ISSN: 2167-9223
Titre abrégé: Amyotroph Lateral Scler Frontotemporal Degener
Pays: England
ID NLM: 101587185

Informations de publication

Date de publication:
08 2022
Historique:
pubmed: 1 10 2021
medline: 20 7 2022
entrez: 30 9 2021
Statut: ppublish

Résumé

An innovative approach to patient management, evidence-based policy development, and clinical drug trials is required to provide personalized care and to improve the likelihood of finding an effective treatment for Motor Neurone Disease (MND). The MiNDAus Partnership builds on and extends existing national collaborations in a targeted approach to improve the standard and coordination of care for people living with MND in Australia, and to enhance the prospects of discovering a cure or treatment. Relationships have been developed between leading clinical and research groups as well as patient-centered organizations, care providers, and philanthropy with a shared vision. MiNDAus has established a corporate structure and meets at least biannually to decide on how best to progress research, drug development, and patient management. The key themes are; (i) empowering patients and their family carers to engage in self-management and ensure personalized service provision, treatment, and policy development, (ii) integration of data collection so as to better inform policy development, (iii) unifying patients and carers with advocacy groups, funding bodies, clinicians and academic institutions so as to inform policy development and research, (iv) coordination of research efforts and development of standardized national infrastructure for conducting innovative clinical MND trials that can be harmonized within Australia and with international trials consortia. Such a collaborative approach is required across stakeholders in order to develop innovative management guidelines, underpinned by necessary and evidence-based policy change recommendations, which, will ensure the best patient care until a cure is discovered.

Identifiants

pubmed: 34590512
doi: 10.1080/21678421.2021.1980889
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

321-328

Auteurs

Steve Vucic (S)

Brain and Nerve Research Center, Concord Clinical School, University of Sydney and Concord Hospital, Sydney, Australia.

Naomi Wray (N)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.

Anjali Henders (A)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.

Robert D Henderson (RD)

Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, Australia.

Paul Talman (P)

Deakin University, University Hospital Geelong, Geelong, Australia.

Susan Mathers (S)

Department of Neurology, Calvary Health Care Bethlehem Monash University, Melbourne, Australia.

Matthew Bellgard (M)

Office of eResearch, Queensland University of Technology, Brisbane, Australia.

Samar Aoun (S)

Perron Institute for Neurological and translational Science, Perth, Western Australia.
La Trobe University, Melbourne, Victoria.

Carol Birks (C)

Motor Neurone Disease Australia, Australia.

Gethin Thomas (G)

Motor Neurone Disease Australia, Australia.

Catherine Hansen (C)

Thomas MND Research Group, Adelaide, South Australia, Australia.

Geoff Thomas (G)

Thomas MND Research Group, Adelaide, South Australia, Australia.

Anne Hogden (A)

Australian Institute of Health Service Management, University of Tasmania, Hobart, Tasmania, Australia.

Merrilee Needham (M)

Department of Neurology, Fiona Stanley Hospital, CMMIT Murdoch University and School of Medicine, University of Notre Dame, Western Australia, Perth, Australia.

David Schultz (D)

Department of Neurology, Flinders Medical Centre, Flinders Drive, Bedford Park, South Australia, Australia.

Tina Soulis (T)

Neuroscience Trials Australia, Melbourne, Australia.

Bec Sheean (B)

FightMND, Melbourne, Australia.

Jane Milne (J)

MND and Me Foundation, Brisbane, Queensland, Australia.

Dominic Rowe (D)

MCentre for Motor Neurone Disease Research, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney, Australia.

Margie Zoing (M)

Brain and Mind Center, University of Sydney, University of Sydney, Sydney, Australia.
Department of Neurology, Royal Prince Alfred Hospital, Camperdown, Australia.

Matthew C Kiernan (MC)

Brain and Mind Center, University of Sydney, University of Sydney, Sydney, Australia.
Department of Neurology, Royal Prince Alfred Hospital, Camperdown, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH